Slide 1: Q4'25 & FY25 Financial Results Webcast & Call
Q4’25 & FY25 Financial Results Webcast & Call March 23, 2026
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation
Slide 3: Bionano is among the leaders transforming pathology from its analog roots into a more digital future
Bionano is among the leaders transforming pathology from its analog roots into a more digital future Cytogenetics Molecular Anatomic Pathology/Clinical Pathology H&E Karyotyping FISH CMA RNA (Transcriptomics) DNA (Sequencing) Flow cytometry/Mass spectrometry staining Analog Panels Whole (hotspot/act
Slide 4: Q4 & FY 2025 Results
Q4 & FY 2025 Results 9.0 $8.0 $7.4 8.0 $6.7 $8.0M 7,554 43% 9 7.0 $6.5 Q4 Flowcells Q4 Non-GAAP Q4 Revenue Q4 New OGM 6.0 Sold Gross Margin (3%) vs. Q4’24 Installations (6%) vs. Q4’24 +1% vs. Q4’24 5.0 4.0 3.0 30,171 47% $28.5M FY25 Flowcells FY25 Non- 32 2.0 FY25 Revenue GAAP Gross FY25 New OGM Sol
Slide 5: Strategic pillars
Strategic pillars Increase OGM utilization by Support & sustain the routine users by supporting installed base of routine menu expansion & improving ease OGM & VIA software users of use with VIA and Ionic adoption Improve profitability and Build support needed scalability with lower costs, for OGM r
Slide 6: FY 2025 consumable and software revenue showed growth, in line with new strategy to focus on routine users
FY 2025 consumable and software revenue showed growth, in line with new strategy to focus on routine users Q4 2025 FY 2025 30,307 30,171 Flowcells Sold 8,058 7,554 4,278 1,683 588 408 In connection to new +9% customer sales (4%) 7,470 26,029 28,488 7,146 To existing customer base Q4 2024 Q4 2025 FY
Slide 7: Routine Use customers account for 83% of consumables revenues
Routine Use customers account for 83% of consumables revenues; those with a validated OGM protocol average $131K per site per year 321 ~130 ~60 ~55 Global OGM Routine Use Routine Use Routine Use Sites Customers Customers Customers Dec 31, 2025 40% of Total Sites intend to validate OGM validated OGM
Slide 8: Upgrades to software and compute platforms to make analysis of OGM, microarray, and NGS data easier
Upgrades to software and compute platforms to make analysis of OGM, microarray, and NGS data easier, faster, and more accurate Software Platforms VIA 7.2 Solve 3.8.3 Broadens OGM workflow to Expands structural variant (SV) control include constitutional genetic database and improves accuracy and dis
Slide 9: Record number of new publications in Q4 2025 and growing number of published human clinical research genomes
Record number of new publications in Q4 2025 and growing number of published human clinical research genomes 136 new publications in Q4 2025 (+25% y/y) 1190 human clinical research genomes published across a range of applications in Q4 2025 reaching nearly 12,700 in total 450 12,000 ~500 before 2021
Slide 10: New Category I CPT code covering OGM use in genetic disorders and a 47% price increase
New Category I CPT code covering OGM use in genetic disorders and a 47% price increase for code used for hematologic malignancies AMA CPT Code for OGM in Constitutional Genetic AMA CPT Code for OGM in Hematologic Disorders (new in 2026) Malignancies (47% price increase in 2026) Current Code # 81354
Slide 11: 2025 showed stabilization of gross margin and cost structure following substantial improvements
2025 showed stabilization of gross margin and cost structure following substantial improvements over the last two years Reduced non-GAAP operating expenses1 Improved non-GAAP gross margin1 to 43% by 9% y/y in Q4 2025 in Q4 2025, compared to non-GAAP core gross margin of 42%2 in Q4 2024 Non-GAAP Oper
Slide 12: 2026 Bionano Symposium Highlights
2026 Bionano Symposium Highlights 1200+ 35 Registrants from Speakers from + 50 73 6 12 4 Posters Countries Continents Countries Continents © Cop yrig ht 202 6 Bion ano Geno mics, Inc.
Slide 13: Featured Speakers from Bionano Symposium 2026
Featured Speakers from Bionano Symposium 2026 NETWORKS INCREASING OGM OGM IMPACT IN COMPLEX 2026: THE YEAR TO SCALE-UP SCALING FOR THE FUTURE IMPLEMENTATION SAMPLES Agnès Daudignon, PhD Ying S. Zou, MD, PhD, FACMG Alexander Hoischen, PhD Adam Smith, PhD, FACMG Radboud University Medical Center, CHU
Slide 14: Initiating Q1 2026 and full year 2026 guidance
Initiating Q1 2026 and full year 2026 guidance Initiating FY’26 revenue: $30 – $33M Initiating Q1’26 revenue: $6.5 – $6.7M Cash Runway into 2027 © Cop yrig ht 202 6 Bion ano Geno mics, Inc. 14
Slide 15: Thank you.
— Thank you.
Slide 16: Statement regarding use of non-GAAP financial measures
Statement regarding use of non-GAAP financial measures To supplement Bionano’s financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), the Company has provided non-GAAP gross margin and non-GAAP operating expense in this presentation, each of which is a no
Slide 17: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Ended December 31, Years Ended December 31, 2025 2024 2025 2024 GAAP gross margin: GAAP revenue $ 7,951,000 $ 8,163,000 $ 28,508,000 $ 30,776,000 GAAP cost of revenue 4,552,000 4,746,000 15,323,000 30,396,000 GAAP gross p